loading page

Phenotypes and Clinical Outcomes of Omalizumab and Mepolizumab treated Difficult Asthma patients
  • +10
  • Wei Chern Gavin Fong,
  • Adnan Azim,
  • Deborah Knight,
  • Heena Mistry,
  • Anna Freeman,
  • Mae Felongco,
  • Aref Kyyaly,
  • Matthew Harvey,
  • Patrick Dennison,
  • Hongmei Zhang,
  • Peter Howarth,
  • S Arshad,
  • Ramesh Kurukulaaratchy
Wei Chern Gavin Fong
Isle of Wight NHS Trust

Corresponding Author:gavinfwc@doctors.org.uk

Author Profile
Adnan Azim
University of Southampton Division of Clinical and Experimental Sciences
Author Profile
Deborah Knight
University Hospital Southampton NHS Foundation Trust
Author Profile
Heena Mistry
Isle of Wight NHS Trust
Author Profile
Anna Freeman
University of Southampton Division of Clinical and Experimental Sciences
Author Profile
Mae Felongco
University of Southampton Division of Clinical and Experimental Sciences
Author Profile
Aref Kyyaly
University of Southampton Division of Clinical and Experimental Sciences
Author Profile
Matthew Harvey
University of Southampton Division of Clinical and Experimental Sciences
Author Profile
Patrick Dennison
University Hospital Southampton NHS Foundation Trust
Author Profile
Hongmei Zhang
University of Memphis
Author Profile
Peter Howarth
University of Southampton
Author Profile
S Arshad
Isle of Wight NHS Trust
Author Profile
Ramesh Kurukulaaratchy
University of Southampton Division of Clinical and Experimental Sciences
Author Profile

Abstract

Introduction Real-world data on Omalizumab (OMA) and Mepolizumab (MEPO) can inform their use in severe asthma (SA). We studied patients in the Wessex AsThma CoHort of difficult asthma (WATCH) to: 1. Phenotypically compare OMA or MEPO treated patients against a SA, non-biologic group (SNB). 2. Assess clinical responses to OMA and MEPO. 3. Assess the spectrum of responses to these biologics. Methods We retrospectively phenotyped biologic naïve patients from WATCH (N=478) commenced on OMA (N=105) or MEPO (N=62) compared to SNB (N=178). Biologic response was gauged using standard criteria and response features were identified using logistic regression. Results OMA and MEPO patients were phenotypically distinct. Both drugs significantly reduced exacerbations, acute healthcare encounters (emergency department or hospital admissions), maintenance oral corticosteroid dose, and improved Asthma Control Questionnaire 6 (ACQ6) scores. OMA patients with more exacerbations at baseline (P=0.024), less acute healthcare encounters (P=0.050), and no anxiety (P=0.008) were more likely to respond to it. Lower baseline ACQ6 was independently associated with higher odds of MEPO response (P=0.007). Combined (OMA or MEPO) non-responders had significantly more psychological co-morbidities and worse baseline subjective disease markers compared to responder groups. Current criteria used to measure trial outcomes for MEPO, but not OMA, missed some modalities of response. Conclusion In a difficult asthma cohort, OMA and MEPO were used for distinct SA phenotypes, yet both were multidimensionally efficacious. Among these phenotypes, some clinical features associated with response were identified which emphasized the importance of addressing treatable traits when considering biologic therapy.